[Management of clinical or biological abnormalities during therapeutic trials]

Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015

[Focusing on peritoneal dialysis adequacy].

Nephrologie & therapeutique·2013

[Choroidal melanoma treated by protontherapy: anatomical and functional results at Strasbourg University Medical Center].

Journal francais d'ophtalmologie·2013

Points of view on adverse drug reactions terminology.

Therapie·1998

[Good practices of publication of clinical cases of pharmacovigilance: comments, Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance: commentary].

Therapie·1997

[Iodine 125 curietherapy of choroidal melanomas. Values of the technique and initial results].

Journal francais d'ophtalmologie·1996

[Five years of ISO 9001 certification in pharmacotoxicology: Experience feedback and implementation modalities in vigilance structures].

Therapie·2026

Epidemiology and risk factors of severe cutaneous drug reactions and evaluation through available databases.

Therapie·2026

Characteristics of patients with opioid/benzodiazepine use disorder in a specialized consultation unit for prescription drug addiction: A cross-sectional study.

Therapie·2026

Anhedonia and neuropsychotropics: A pharmacovigilance-pharmacodynamic study.

Therapie·2026

[Biological pharmacology: A white paper].

Therapie·2026

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026

Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation.

European journal of nuclear medicine and molecular imaging·2026

Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.

Gut·2026

Bridging preclinical and clinical efficacy of SIK2/SIK3 inhibition in inflammatory bowel disease through integrated murine, patient-derived models, and phase 2a trial-based analyses.

Journal of Crohn's & colitis·2026

Engineered nano-delivery platforms targeting ferroptosis-evasion pathways to reverse tumor drug resistance.

Biochimica et biophysica acta. Reviews on cancer·2026

Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.

Biochimica et biophysica acta. Reviews on cancer·2026

Related Experiment Videos

[Management of clinical or biological abnormalities during therapeutic trials]

Related Concept Videos

Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship.

[Focusing on peritoneal dialysis adequacy].

[Choroidal melanoma treated by protontherapy: anatomical and functional results at Strasbourg University Medical Center].

Points of view on adverse drug reactions terminology.

[Good practices of publication of clinical cases of pharmacovigilance: comments, Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance: commentary].

[Iodine 125 curietherapy of choroidal melanomas. Values of the technique and initial results].

[Five years of ISO 9001 certification in pharmacotoxicology: Experience feedback and implementation modalities in vigilance structures].

Epidemiology and risk factors of severe cutaneous drug reactions and evaluation through available databases.

Characteristics of patients with opioid/benzodiazepine use disorder in a specialized consultation unit for prescription drug addiction: A cross-sectional study.

Anhedonia and neuropsychotropics: A pharmacovigilance-pharmacodynamic study.

[Biological pharmacology: A white paper].

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation.

Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer.

Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.

Bridging preclinical and clinical efficacy of SIK2/SIK3 inhibition in inflammatory bowel disease through integrated murine, patient-derived models, and phase 2a trial-based analyses.

Engineered nano-delivery platforms targeting ferroptosis-evasion pathways to reverse tumor drug resistance.

Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.

Related Experiment Videos

[Management of clinical or biological abnormalities during therapeutic trials]

Related Concept Videos

Related Articles